Bispecific Antibodies vs CAR T-Cells: Mechanistic and Practical Distinctions
| Differentiating BCMA Bispecific Antibodies in R/R Multiple Myeloma: Real-World Integration and Patient-Centered Management This Around the Practice discussion series, BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Real-World Integration and Patient-Centered Management, brings together leading experts Sundar Jagannath, MBBS, Icahn School of Medicine at Mount Sinai Hospital; Ajay Nooka, MD, MPH, FACP and Nisha Joseph, MD (Winship Cancer Institute of Emory University); Mohan Krishnamachary, MD (Suburban Hematology Oncology Associates); and Donna Catamero, MSN, ANP-BC, OCN, CBCN (Icahn School of Medicine at Mount Sinai Hospital), for a focused conversation recorded at ASH 2025. |
|
|
Featured Video |
 |
| Bispecific Antibodies vs CAR T-Cells: Mechanistic and Practical Distinctions Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment. |
|